- December 15, 2022
Time: 13:00-17:00 Central European Time | 7:00 AM-11:00 AM United States EST
This meeting will be held in virtual format only. FDA and EMA seek to bring together scientists, clinicians, industry representatives and regulators to discuss alternative strategies to support the development of novel monoclonal antibody therapies including those based on prototype products that have demonstrated safety and efficacy in clinical trials.
Note: This meeting is intended for experts in the field and/or people actively involved in the topic of the meeting.
This meeting will be held in virtual format only. Advanced registration is required for online observer attendance. To register for this workshop and receive the meeting link, please use the registration link.